Rambam MedTech

Rambam MedTech is the commercialization arm of Rambam Health Care Campus in Haifa, one of Israel’s largest hospital networks and a substantial clinical research operation. Its role is to translate the clinical insights and inventions emerging from the hospital’s physicians into operating medical device and digital health companies.

The thesis is anchored to the clinical reality of running a large, busy hospital. Rambam’s physicians see problems before market researchers do, and the MedTech program exists to capture those insights and structure them as commercial opportunities. Activity concentrates on medical devices and digital health, with attention to oncology, ophthalmology, cardiovascular care, and the broader categories where the hospital’s clinical excellence is concentrated. AI shows up increasingly in the portfolio as physicians collaborate with engineers on imaging, diagnostics, and decision-support tools that are grounded in real clinical workflows.

Checks fall below two hundred and fifty thousand dollars at the Pre-Seed and Seed stages, structured to underwrite the earliest commercialization work and patent filings rather than to lead institutional venture rounds. Geography is anchored in companies emerging from Rambam clinicians and partnerships, with portfolio companies typically targeting global markets in the US and Europe. The program is positioned as a clinical-origin partner that bridges from physician-inventors to external venture investors, and the structure of engagement reflects that role.

The team operates at the intersection of hospital administration, clinical practice, and commercial development. Founders work directly with physician-inventors and commercialization staff, and the engagement is grounded in clinical credibility rather than purely commercial pattern-matching. The diligence is heavy on clinical defensibility, regulatory pathway, and the translation of a hospital-floor insight into a manufacturable, sellable product. The relationships within Rambam itself are the program’s most distinctive asset, providing access to clinical evidence, KOL development, and the operational reality of how a product would actually be used.

In practice, Rambam MedTech offers a bundle that pure venture investors cannot replicate. It provides clinical credibility, access to physician-inventors and clinical evidence, and the ability to validate products in a real hospital environment before commercial launch. The program is direct about scope. It does not engage with companies disconnected from Rambam clinicians or clinical workflows, and the relationship is institutional rather than conventional. For founders building medical devices or digital health products in oncology, ophthalmology, or cardiovascular care with credible clinical roots at Rambam, the program is one of the more substantive early-stage clinical-origin partners in Israel. The conversations are clinically grounded, the diligence is rigorous, and the path forward typically involves bringing in venture investors and clinical partners quickly to scale a product whose origin in real clinical practice is one of its strongest assets.